
    
      This Phase 1 Study is an open-label, non-randomized, dose escalation, safety, efficacy,
      pharmacokinetic, and pharmacodynamic evaluation study of INA03 administered as a single agent
      IV infusion every 2 weeks to patients â‰¥18 years of age with R/R AML, MLL, or ALL.

      The study will be performed in 2 parts: a Dose Titration for Day 1 study (Part 1) followed by
      a Dose Escalation Part (Part 2) of INA03 used as monotherapy.
    
  